Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects with perennial allergic rhinitis who satisfy all of the following main criteria:~  * Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree, after the pretreatment observation period.~ * Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust-mite antigen).~ * Male or female outpatients aged 5 to 15 years at the time of providing informed consent.~Exclusion Criteria:~* Subjects for whom any of the main exclusion criteria below is applicable will not be registered in this study.~  * Subjects with coexisting tuberculous disease or lower respiratory tract infection and subjects who have a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment at the time of registration~ * Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics~ * Subjects with repeated epistaxis~ * Subjects who have nasal septum ulcers, nasal surgery, or nasal trauma, which have not healed~ * Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor~ * Subjects with complication of vasomotor rhinitis or eosinophilic rhinitis.~ * Subjects with nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Mometasone furoate nasal spray (MFNS) (50 μg spray device) (Type: EXPERIMENTAL): The dose will be as follows:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks
- MF placebo nasal spray (Type: PLACEBO_COMPARATOR): Administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).